Apoptosis
There are many forms of cell death, most of which can be triggered by a variety of stimuli and physiological conditions. The often compared are apoptosis and necrosis. Apoptosis has become the focus of research area due to its complex nature and the different roles of maintaining healthy and self-sustaining biological entities. On the other hand, necrosis is a form of cell damage against acute external injury and trauma, leading to passive cell death and causing an inflammatory response. [1]
The BCl-2 family has been identified as its important role in apoptosis. The BH domain promotes interaction of family members with one another and may be indicative of pro-apoptotic or anti-apoptotic functions. Usually the BCL-2 family have been classified into one of three subfamilies; anti-apoptosis, BH3 only (pro-apoptotic) and pro-apoptotic proteins. The great promise for cancer therapy has been shown in recent research about BCL-2 targeting.[2]
In the cell cycle, apoptosis acts as a fail-safe measure to prevent fidelity and proliferation quality. Although a certain degree of genetic variation is allowed and evolution is promoted, regenerative cells with extensive genetic errors and cell damage are subject to apoptosis. P53 is the Key role in the cell cycle system which initiate the apoptosis in certain cell types. P53 is a widely studied tumor suppressor. The p53 tumor suppressor gene is most frequently mutated in cancer cells (mutation occurs in more than 50% of human cancers) [3], which makes the restriction mechanism ineffective. Tumorigenesis is likely to commence when the p53-based preventive system loses its function completely.
Expression of stimuli, such as DNA damage, hypoxia and activation of certain oncoproteins (eg, Myc, Ras) are dependent on the apoptotic pathway of p53 [4]. The transactivation function of p53 plays an important role in inducing apoptosis, the pro-apoptotic proteins, Bax and lgF-Bp3, are transcriptional targets of p53.[5] As a well-known tumor suppressor, p53 is recognized for its ability to initiate apoptosis in the cell cycle and its ability to induce cell arrest and DNA repair in regenerative cells. In addition to p53, there are many other cell cycle regulators that can affect apoptosis (eg, pRb, p21).
Many studies have emphasized the importance of apoptosis in the self-defense mechanism or immune system. The immune system is responsible for rendering the host resistant to a variety of external pathogens. Apoptosis is an integral part of the immune system and helps maintain the homeostasis of the immune system. Secondly, the immune system relies on apoptosis to eliminate unwanted functional maturation of T cells and B cells [6]. Finally, apoptosis confers cytotoxicity to certain cell types (ie, cytotoxic T lymphocytes and natural killer cells). A well-coordinated disruption protocol allows these cells to destroy target cells while the target cells remain intact. Cytotoxic T lymphocytes (CTLs) can induce target cell death in two ways, one of which involves perforin and granzymes.
- Majno G. and Joris I. (1995) Apoptosis, oncosis, and necrosis. An overview of cell death. Am. J. Pathol. 146, 3–15
- Zhiqing Liu, et al. Drug Discov Today. 2016 Jun; 21(6): 989–996.
- Wang X.W. and Harris C.C. (1997) p53 tumor-suppressor gene: clues to molecular carcinogenesis. J. Cell. Physiol. 173, 247–255 10.1002/(SICI)1097-4652(199711)173:2%3c247::AID-JCP30%3e3.0.CO;2-A.
- Levine A.J. (1997) p53, the cellular gatekeeper for growth and division. Cell 88, 323–331 10.1016/S0092-8674(00)81871-1.
- Owen-Schaub LB,et al. Owen-Schaub LB,Wild-type human p53 and a temperature-sensitive mutant induce Fas/APO-1 expression. Mol Cell Biol. 1995 Jun; 15(6):3032-40.
- Russell J.H. (1995) Activation-induced death of mature T cells in the regulation of immune responses. Curr. Opin. Immunol. 7, 382–388 10.1016/0952-7915(95)80114-6.
-
NVP-CGM097
Catalog No. A16326 -
HDM201
Catalog No. A16834 -
Difopein
Catalog No. A14917 -
GSK2656157
Catalog No. A13577 PERK 抑制剂GSK2656157是PERK酶活性的ATP竞争性抑制剂,IC50为0.9 nmol/L。 对于PER(K)IC50值> 100 nmol/L,对300种激酶组合具有高度选择性。 了解更多 -
Salubrinal
Catalog No. A12676 eIF2α dephosphorylation 抑制剂Salubrinal是细胞磷酸酶复合物的可渗透细胞的选择性抑制剂,可将真核翻译起始因子2亚基α(eIF2α)磷酸化。保护细胞免受内质网应激诱导的细胞凋亡(EC50?15 μM)。 了解更多 -
ISRIB
Catalog No. A14302 -
GSK2606414
Catalog No. A12792 PERK 抑制剂GSK2606414是口服有效的选择性PERK抑制剂,IC50为0.4 nM。 了解更多 -
ISRIB (trans-isomer)
Catalog No. A13816 -
YM155 (Sepantronium Bromide)
Catalog No. A11002 Survivin 抑制剂YM155 (Sepantronium Bromide)是一种新型小分子存活蛋白抑制剂,IC50为0.54 nM,可抑制存活蛋白启动子活性。 了解更多 -
RIP2 kinase inhibitor 1
Catalog No. A16312 RIP2 kinase 抑制剂RIP2 kinase inhibitor 1 是从专利WO/2014043446 A1(化合物实施例1)中提取的受体相互作用蛋白2(RIP2)激酶抑制剂。 了解更多 -
RIP2 kinase inhibitor 2
Catalog No. A16313 RIP2 kinase 抑制剂RIP2 kinase inhibitor 2 是从专利WO/2014043437 A1(化合物实施例9)中提取的受体相互作用蛋白2(RIP2)激酶抑制剂。 了解更多 -
GSK3145095
Catalog No. A19427 RIP1 kinase inhibitorGSK3145095 is a RIP1 kinase inhibitor with an IC50 of 6.3 nM . 了解更多 -
GSK2982772
Catalog No. A19380 RIP1 kinase inhibitorGSK2982772 is a potent, orally active and ATP competitive RIP1 kinase inhibitor with IC50 values of 16 nM and 20 nM for human and monkey RIP1, respectively. 了解更多 -
RIPK1-IN-3
Catalog No. A19023 RIPK1 inhibitorRIPK1-IN-3 (Example 38), a RIPK1 inhibitor, extracted from patent WO2018148626A1, possesses anti-inflammatory proprieties. 了解更多 -
RIPK1-IN-7
Catalog No. A18940 RIPK1 inhibitorRIPK1-IN-7 is a potent and selective RIPK1 inhibitor with a Kd of 4 nM and an enzymatic IC50 of 11 nM. RIPK1-IN-7 exhibits excellent antimetastasis activity in the experimental B16 melanoma lung metastasis model. 了解更多 -
RIPK1-IN-4
Catalog No. A21029 RIP1 kinase inhibitorRIPK1-IN-4 (compound 8) is a potent and selective type II kinase inhibitor of receptor interacting protein 1 (RIP1) kinase and binds to a DLG-out inactive form of RIP1 with an IC50s of 16 nM and 10 nM for RIP1 and ADP-Glo kinase. 了解更多 -
Selonsertib
Catalog No. A15991 ASK1 抑制剂Selonsertib是一种凋亡信号调节激酶1(ASK1)的口服生物利用抑制剂,具有潜在的抗炎,抗肿瘤和抗纤维化活性。 了解更多 -
Regorafenib (BAY 73-4506)
Catalog No. A10250 VEGFR 抑制剂Regorafenib (BAY 73-4506)是一种多激酶抑制剂,IC50为17、40和69 nM c-KIT,VEGFR2,B-Raf。Regorafenib(BAY 73-4506)是一种针对肿瘤及其脉管系统的口服生物利用型多激酶抑制剂。 了解更多 -
Danusertib (PHA-739358)
Catalog No. A10715 Aurora 抑制剂Danusertib (PHA-739358)是Aurora A/B/C的Aurora激酶抑制剂,在无细胞分析中的IC50为13 nM/79nM/61 nM,对Abl,TrkA,c-RET和FGFR1以及更低的浓度具有中等效力 对Lck,VEGFR2/3,c-Kit,CDK2等有效。 了解更多 -
Regorafenib monohydrate
Catalog No. A15218 Tyrosine kinase 抑制剂Regorafenib monohydrate是VEGFR1/VEGFR2/VEGFR3/PDGFRβ/Kit/RET和Raf-1的多靶点抑制剂,IC50分别为13 nM/4.2 nM/46 nM/22 nM/7 nM/1.5 nM和2.5 nM。 了解更多 -
Regorafenib Hydrochloride
Catalog No. A11546 VEGFR1/2/3/PDGFRβ/Kit/RET/Raf-1 inhibitorRegorafenib Hydrochloride is a multi-target inhibitor for VEGFR1/2/3, PDGFRβ, Kit, RET and Raf-1 with IC50s of 13/4.2/46, 22, 7, 1.5 and 2.5 nM, respectively. 了解更多 -
cis-Pralsetinib
Catalog No. A21586 RET inhibitorcis-Pralsetinib (cis-BLU-667) is a highly potent and selective inhibitor of rearranged during transfection (RET), with IC50s ranging from 0.3 to 0.4 nM for WT RET and four enzyme variants (V804L, V804M, M918T, CCDC6-RET), and with broad, robust and anti-tumor activity against multiple RET-driven solid tumor types. 了解更多 -
CID 2011756
Catalog No. A12416 -
kb NB 142-70
Catalog No. A12423 -
CID 755673
Catalog No. A13804 PKD 抑制剂CID755673是一种具有细胞活性的泛PKD1/2/3抑制剂,IC50值分别为180 nM,280nM,以及227 nM。 了解更多 -
CID 797718
Catalog No. A13809 PKD1 抑制剂CID797718是CID755673(Adooq目录号A13804)的结构类似物。它是效力降低10倍的PKD1抑制剂,IC50值为7.0+/-0.8 uM。 了解更多 -
CRT-0066101
Catalog No. A16318 PKD 抑制剂CRT-0066101是有效,选择性的蛋白激酶D(PKD)抑制剂;抑制所有PKD同工型(PKD1,PKD3和PKD2的IC50值分别为1、2和2.5 nM)。 了解更多